Dabrafenib and trametinib in BRAFV600E mutated glioma.

about

Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling.Imaging and Histopathologic Nuances of Epithelioid Glioblastoma.

P2860

Q52321854-236C48C5-CFDE-4687-9BFE-AF5AB1CFD262 Q55347746-FD407113-77A4-49DE-AF54-0E768B312985

P2860

Dabrafenib and trametinib in BRAFV600E mutated glioma.

Item

http://www.wikidata.org/entity/Q49565156

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dabrafenib and trametinib in BRAFV600E mutated glioma.

@en

Dabrafenib and trametinib in BRAFV600E mutated glioma.

@nl

type

Item

label

Dabrafenib and trametinib in BRAFV600E mutated glioma.

@en

Dabrafenib and trametinib in BRAFV600E mutated glioma.

@nl

prefLabel

Dabrafenib and trametinib in BRAFV600E mutated glioma.

@en

Dabrafenib and trametinib in BRAFV600E mutated glioma.

@nl

P1476

Dabrafenib and trametinib in BRAFV600E mutated glioma.

@en

P2093

Neil Kitchen

http://www.w3.org/2001/XMLSchema#string

Nicholas F Brown

http://www.w3.org/2001/XMLSchema#string

Thomas Carter

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

The 2007 WHO classification of tumours of the central nervous system

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Mutations of the BRAF gene in human cancer

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib

Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases

Resistance to BRAF inhibition in melanomas.

Pleomorphic xanthoastrocytoma: what do we really know about it?

P304

291-296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2217/CNS-2017-0006

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul Mulholland

P577

2017-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28984141

http://www.w3.org/2001/XMLSchema#string

P932

6004887

http://www.w3.org/2001/XMLSchema#string

Dabrafenib and trametinib in BRAFV600E mutated glioma.

about

P2860

P2860

Dabrafenib and trametinib in BRAFV600E mutated glioma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932